Presented herein are compositions and methods for generating stem cell derived retinal tissue and isolated retinal progenitor cells for use in the treatment of retinal degenerative diseases and disorders.

Disclosed are hydrogel matrixes for use in recruitment and reprogramming of CAR T cells, CAR NK cells, CAR NK T cells, CAR macrophage, Tumor infiltrating NK cells, tumor infiltrating lymphocytes, and marrow infiltrating lymphocytes.

The present invention provides piperidin-4-y1 azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.

A method of treating post-surgical edema includes a step of administering an effective amount of a pharmaceutical composition to a subject identified a risk of post-surgical edema. The pharmaceutic composition include a retinoic acid component selected from the group consisting of 9-cis retinoic acid, geometric isomers of 9-cis retinoic acid, metabolites of 9-cis retinoic acid, substituted derivatives thereof, and combinations thereof. An implantable pellet including the retinoic acid component is also provided.

An article of manufacture according to the present invention comprises a composition including a glycosaminoglycan, a local anesthetic, and a buffer packaged in a syringe or vial constructed from either glass or a plastic selected from the group consisting of cyclic olefin polymer, cyclic olefin copolymer, or high density non-nucleated polypropylene. The composition has unexpectedly improved stability on storage. The composition can be formulated for treatment of a urinary tract disease or condition, such as interstitial cystitis, also known as bladder pain syndrome or hypersensitive bladder syndrome.

Provided herein are polymers of Formula (I), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, compositions, and formulations thereof. The polymers described herein are biocompatible, non-toxic, water compatible, and operationally simple to formulate. Also provided are methods and kits involving the polymers described herein (e.g., methods of using polymers described herein for delivering agents (e.g., for therapeutic, diagnostic, prophylactic, imaging, ophthalmic, intraoperative, or cosmetic use) to a subject, cell, tissue, or biological sample, as part of materials (e.g., biodegradable materials, biocompatible materials, wound dressing (e.g., bandages), drug depots, coatings), or as scaffolds for tissue engineering. Provided are methods for synthesizing the polymers described herein, and polymers described herein synthesized by the synthetic methods described herein. ##STR00001##

The pharmaceutical composition constituted by carboxymethylated starch and citric acid, a citrate, or mixtures thereof, prevents adhesion of injured mesothelial surfaces and the formation of adhesion bands between the mesothelia at the highest level. The composition in gel form acts as a matrix in which connective tissue healing of tissue defects is promoted.

An implantable medical device having a soft tissue interfacing surface comprises at least one soft actuatable capsule having a soft tissue interfacing deflectable membrane configured for cyclical deflection upon actuation of the capsule to modulate the biomechanics of the soft tissue interface during use. The actuatable capsule may comprise an actuation chamber containing a first fluid, a therapeutic chamber containing a second fluid, a deflectable membrane separating the actuation chamber and therapeutic chamber, and an actuation conduit in fluidic communication with the actuation chamber for pneumatic actuation of the actuation chamber. The therapeutic chamber comprises the soft tissue interfacing deflectable membrane which is configured to cyclically deflect during actuation of the capsule and modulate the biomechanics of the soft tissue interface by altering one or more of strain, fluid flow and cellular activity in peri-implant tissue at the soft tissue interface. Methods of reducing fibrotic encapsulation of an implantable medical device are also described.

In an example of a method for making a pulsatile delivery device, one type of charges are generated on a polymeric layer, and charges opposite the one type of charges are generated on a delivery layer including a film forming material and a predetermined substance dispersed throughout the film forming material. The charged polymeric and delivery layers are placed into contact to form a bi-layer structure. A stack with at least two bi-layer structures is formed so that the polymeric layers and the delivery layers are alternating throughout the stack. The stack is sealed so that one of the polymeric layers remains exposed.